ABSTRACT
Introduction
Acquired immune deficiency syndrome (AIDS) that is currently believed to be a critical global health problem [1] . According to WHO statistics (World Health Organization), 33.3 million (31.4 -35.3 million) people suffered from HIV worldwide in 2009. [2] Until 2008, the cumulative number of people died of AIDS was estimated to be more than 33 million [3] . The unpublished data in Iran until December 2009 show that 92.7% of the total 20547 HIV-infected individuals are male. From among this population, 2221 have been diagnosed with AIDS and 3543 died secondary to the complications. Recent studies suggest antiretroviral therapy for patients with CD4 + T cell count ≤ 350/μlit [4] .
Despite the broader coverage of antiretroviral therapy since 2003 [5] , more than 30 million people were diagnosed with HIV in low and middle-income countries in 2009 [6] and from among them, only 36% with CD4 T cell count ≤ 350 /μlit received antiretroviral therapy in HIV/AIDS Patients: A Randomized Double Blind Placebo Controlled Trial the same year [7] .
Iranian the government offers free ART (antiretroviral therapy) to HIV and AIDS patients; the point is that only 6% of the adults and 4 to 14% of the children managed to receive the drugs regularly in 2009 [8] . Apart from the toxic effects of ART, the development of new strains of the virus and subsequently resistance to available medications, especially in areas with acceptable coverage of the therapy, indicate that in addition to ART, other alternative therapies are needed in this regard [9] .
Many studies have reported that in a highly oxidative state, the progress of HIV infection can be promoted to the host [10] . Thus, treating the patients with antioxidants since early stages of the disease is believed to be beneficial.
Selenium (Se) is a micronutrient with antioxidant and immunoregulatory properties [10] . According to the results of several studies, lower serum Se levels correlates with a smaller total number of CD4 + T cells, more advanced stages of infection and higher rates of mortality caused by HIV [13] [14] [15] [16] [17] [18] [19] [20] [21] . Many studies have pointed out the effect of depleted antioxidant agent-like glutathione peroxides-resources which is a result of HIV infection in promoting virus replication and CD4 + T cell count descent [22] [23] [24] . As the infection develops, serum Se concentration diminishes progressively due to several causes including malabsorption caused by chronic infection, infectious diarrhea and HIV-related enteropathy, proteincalorie malnutrition and the inadequate intake of Se through diets [24, 25] . Moreover, HIV contributes to the development of an enzyme with a glutathione peroxidelike structure-Se is a part of this enzyme structurewhich comprises Se. Hypothetically, virus replication leads to the consumption of Se resources of infected T cells, through the development of the abovementioned enzyme [26] . There was a positive correlation between serum Se level and CD4 + T cell count, CD4 CD8 ratio and a negative correlation between this variable and indices of HIV infection progression, i.e. activity of Thymidine kinase and level of 2  microglobulin. There was also a positive correlation between serum Se concentration and hematocrit and serum albumin. In a cross sectional survey conducted in the Iranian research center for HIV/AIDS, Se deficiency (serum Se level < 85 μgr/lit) was reported in 38% of the HIV positive individuals. This is while a healthy male in the control group had significantly lower mean serum Se concentrations [19] . Not many researches have been trials with Se in humans ( Table 1) . Delmas-Beavieux chose 52 HIV positive patients randomly and supplied them with Se and beta carotene supplements and placebo daily for 12 months. They failed to report any improvement in CD4 + T cell count, as for the placebo group. However, glutathione levels-an antioxidant factor were significantly higher, whereas malondialdehyde levels-an indicator of lipid peroxidation were significantly lower in both treated groups [20] . In a clinical trial, 19 HIV and AIDS patients received 400 μgr Se supplements per day. After 70 days, some subjective improvements in the bowel function, appetite and severity of oral condidiasis as well as a decline in the incidence rate of opportunistic infections were achieved [21] . In another trial, taking Se supplements, which contained lower amounts of elemental Se (80μgr daily) for two months, significantly improved serum Se levels in HIV and AIDS patients; it, however, had no Studies in which administration of Se supplement led to an insignificant improvement in CD4 + T cell count.
Studies in which administration of Se supplement led to a significant improvement in CD4 + T cell count.
1) Delmas-Beavieux supplied 52 HIV patients with 250 µgr Se or 30 mgr beta carotene for 12 months, no improvement in CD4 + T cell count was achieved. Gl utathione levels-an antioxidant factor were significantly higher, whereas malondialdehyde levels-an indicator of lipid peroxidation were significantly lower in both treated groups.
2) Cirelli administered 80 µgr Se and 25 mgr vit E to 11 HIV patients for two months. No improvement in CD4 + T cell count was achieved.
3) Look supplied 24 HIV patients with 600 mgr N-acetylcystein together with 500 µgr Se for 24 weeks, no improvement was achieved in absolute CD4 + T cell count, but there was an increase in CD + T cell percentage and CD4 + T/CD8 + T cell ratio. 4) Burbano investigated the effect of 200 µgr daily Se supplement on CD4 + T cell count and hospital admissions of 186 HIV patients. No improvement was achieved in CD4 + T cell count, but there was a decrease in the rate of patients' hospital admissions due to HIV complications.
Hurwitz investigated the effect of 200 µgr daily Se supplement on CD4 + T cell count of 174 HIV patients for 9 months. In the end, there was a significant increase in CD4 + T cell count.
Copyright © 2011 SciRes. [27] . Similarly, taking 200 μgr daily Se supplements for 2 years considerably improved Se levels but had no effect on CD4+T cell count. The number of patients with a decline in CD4 + T cell count of ≤50/μlit, however, was significantly greater in the placebo treated group (46% in contrast with 24% in Se treated group). Hospital admissions due to opportunistic infections were significantly more common in the placebo group (94% in contrast to 42% in the Se group) [28] . A recent trial, stressed that individuals who experienced an increase of at least 26μgr/lit in serum Se levels following the administration of 200μgr daily Se supplements for 9 months (Se responders) were more likely to have a higher CD4 + T count, but a lower viral load. Despite the fact that the effect of Se supplement on CD4 + T cell count was secondary to and a consequence of its impact on viral loud, there was no significant change in CD4 + T count in Se nonresponders and the placebo group [29] . In another trial, 24 asymptomatic HIV patients were supplied with 1800 mgr N-acetyl cystein along with 500 μgr Sodium Selenite daily. In the end, total CD8 + T cell count and its proportion decreased and the proportion of CD4 + T cell and CD4 T cell count CD8 T cell count   ratio increased significantly. No improvement was achieved in CD4 + T cell absolute count. In 9 accidentally chosen patients, the number of HIV RNA copies/μlit did not differ; in 44% of them, however, this value was steady (no increase) after this time [30] . Considering the results of these studies, more documents regarding the beneficial effects of Se supplementation in HIV + /AIDS patients are needed.
Aim
Determining the effect of Se supplementation on CD4 + T lymphocyte count in HIV patients
Objectives
Determining the effects of Se supplementation on  CD4 + T lymphocyte count in HIV patients;  Body mass index (BMI) values of HIV patients;  Hb levels of HIV patients;  The rate of developing opportunistic infections in HIV patients. 
Study Population

Recruitment
Subjects of the study consist of individuals diagnosed with HIV through Western blotting test. Eligible patients meeting the inclusion criteria will be recruited and the others will be excluded (see Table 2 ). We will recruit 100 HIV infected patients with either sufficient or inadequate serum levels of Se (the deficiency criterion is having serum Selenium levels of 85 µg/dl or lower). A detailed written explanation of the study process, names of individuals and institutions in charge, possible benefits and probable adverse effects of the interventions is given to the participants and additional information would be provided upon request. Informed participants will be asked to sign a written informed consent. After baseline assessment completion and signing the informed consent, all patients will be randomized based on age, sex, HIV infection and AIDS by permuted block randomization with 4 numbers block into two groups, each consisting of 50 HIV positive patients. One group will receive placebo, whereas the other will receive Se supplements. The patients and the researchers are both blinded (see Figure 1 ).
Baseline Assessments
In their first visit all participants are required to complete a questionnaire on their demographic information, route of HIV transmission and the number of opportunistic infections during one year prior to the study. A comprehensive physical exam will be performed, a complete medical history will be taken and essential primary lab tests will be performed by the trial clinician in charge (see Table 3 ).
Intervention
This double-blind randomized placebo control trial has 2 arms including the supplement and placebo groups. There will be a treatment course for 6 months and supplement capsules which contain 200 µgr elemental Se or placebo capsules with an inert material will be given to patients for daily administration. Active supplement and placebo capsules will be indistinguishable in colour and taste. Pharmacology faculty laboratory will produce the placebo and supplement capsules. The patients should take one capsule a day and will be recommended to take capsules with a glass of water one hour before lunch. In order to prevent Se toxicity, they will be recommended to take only one capsule per day and not to take two or several capsules together in case they forget to use daily capsules. They will also be asked to bring back the package in the next visit. There will be a 3-month follow up period and a follow up visit in the end.
Follow-Up Assessments
Altogether, we will perform 9 visits (see Table 4 ), the first one is the enrolment session in which patients that meet the inclusion and exclusion criteria will be identified and informed. In the second visit, baseline assessment will be performed and the participants will sign the informed consent. 100 patients will be randomized to receive either supplement or placebo. Finally, the patients Table 3 . Baseline parameters. , 5 th and 6 th months. All patients will be visited at the end of the 3 rd month after intervention termination which will be the 9 th visit. During every monthly and follow up visit, the physician in charge will take a brief history of the last month, focusing on the incidence of opportunistic infection and manifestations of supplement toxicity. A goal directed physiccal examination based on the taken history will be performed to evaluate the two subjects mentioned above. Physical examination will also include weight, height and blood pressure measurement. Measuring the absolute count of CD4 + T lymphocyte will be repeated every 3 months at 5 th , 8 th and 9 th visits in order to evaluate the trend of CD4 + T cells changes. In the 2 nd and 6 th visits, we will measure the plasma level of Se and compare it with the initiating value to determine whether there has been any significant changes. Values of hemoglobin and hematocrite will also be measured in the visit.
Measures of Compliance
The patients will be asked to bring the unused capsules back in the next monthly visit to determine their compliance with taking the drug. The proportion of unused capsules to the total number of the capsules ( unused capsuls number total number of capsules ) will be used as an indicator of the participants' compliance.
Concealment
This study will be double blinded, implying that both participants and the conductors of the trial (individuals providing the patients with their drugs, those performing physical examinations and taking histories in addition to those in charge of performing lab tests) will be unaware whether each patient is receiving supplements or placebo. In this regard, the placebo that contains inactive material will be indistinguishable from supplements based on their color and taste. Additionally, all drug packages will be randomly coded and the statistical analyzer will be the only informed person.
